Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II consolidation with fractionated 90Y-epratuzumab after R-CHOP in older adults with disseminated aggressive B-cell lymphoma
2007-002414-19Phase 2Active
- Sponsor
- Goelams
- Start
- Nov 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of epratuzumab in diffuse large B-cell lymphoma (DLBCL), large-cell lymphoma and B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma, sponsored by Goelams. Primary endpoint: Event-free survival at 2 years. Started Nov 2007; status: active.
02
Drugs
epratuzumab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)large-cell lymphomaB-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma
Beyond the preview
Go deeper on 2007-002414-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-002414-19.